Skeletal involvement in adult patients with endogenous hypercortisolism
The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Overt endogenous glucocorticoid excess is a well-recognized cause of bone loss and osteoporotic fractures. Cortisol excess inhibits bone formation, increases bone resorption, impairs calcium absorption from the gut, and affects the secretion of several hormones (in particular gonadotropins and GH), cytokines, and growth factors, influencing bone metabolism. The glucocorticoid excess mainly affects trabecular bone, leading to vertebral fractures in up to 70% of patients. Osteoporotic fractures may be the presenting symptom of an otherwise silent glucocorticoid excess and can precede the diagnosis of hypercortisolism by up to 2 yr. The removal of glucocorticoid excess leads to a recovery of bone mass which is, however, often incomplete and delayed, although it reduces the risk of osteoporotic fractures. Bisphosphonate therapy has been suggested to be useful in maintaining bone mass in these patients. Subclinical hypercortisolism, a condition of impaired hypothalamic- adrenal-axis homeostasis without the classical signs and symptoms of glucocorticoid excess, is a recently defined entity, which has been shown to be associated to increased bone resorption, bone loss, and high prevalence of vertebral fractures regardless of gonadal status. However, data about the effect of this subtle glucocorticoid excess on bone are still scarce and conflicting. Moreover, it is not yet known whether removing the cause of subclinical hypercortisolism leads to a recovery of bone mass and reduces the risk of osteoporotic fractures. Finally, recent data suggest that subclinical hypercortisolism is a common and underrated finding in patients with established osteoporosis. In summary, it is crucial to evaluate the risk of osteoporosis and fractures in patients with glucocorticoid excess; on the other hand, it also seems advisable to screen for glucocorticoid excess patients with osteoporotic fractures without known secondary causes of osteoporosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, cortisol can negatively affect bone health73 and exacerbate age-related bone density decline, possibly contributing to the development of osteosarcopenic obesity74.”
From Sarcopenic obesity in older adults: a clinical overview (2024) · cites this paper as [73]
Citations
Cites
Weinstein, R. S., Jilka, R. L., Parfitt, A. M., & Manolagas, S. C. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2799 · Cited by 1,753
Diagnosis and complications of Cushing’s syndrome: a consensus statement
Arnaldi, G., Angeli, A., Atkinson, A. B., Bertagna, X., Cavagnini, F., Chrousos, G. P., Fava, G. A., Findling, J. W., Gaillard, R. C., Grossman, A. B., et al. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030871 · Cited by 1,362
Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism
(2018) · Wiley eBooks · doi:10.1002/9781119266594 · Cited by 1,105
Cushing, H. (1964) · Journal of Neurosurgery · doi:10.3171/jns.1964.21.4.0318 · Cited by 851
Hofbauer, L. C., Gori, F., Riggs, B. L., Lacey, D. L., Dunstan, C. R., Spelsberg, T. C., & Khosla, S. (1999) · Endocrinology · doi:10.1210/endo.140.10.7034 · Cited by 794
O’Brien, C. A., Jia, D., Plotkin, L. I., Bellido, T., Powers, C. C., Stewart, S. A., Manolagas, S. C., & Weinstein, R. S. (2004) · Endocrinology · doi:10.1210/en.2003-0990 · Cited by 771
Laurence, M. (2000) · The Journal of Bone and Joint Surgery. British volume · doi:10.1302/0301-620x.82b7.0821087b · Cited by 675
Molecular Basis and Clinical Application of Biological Markers of Bone Turnover*
CALVO, M. S., EYRE, D. R., & GUNDBERG, C. M. (1996) · Endocrine Reviews · doi:10.1210/edrv-17-4-333 · Cited by 518
Rossi, R. (2000) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.4.1440 · Cited by 419
Mechanisms of Glucocorticoid Action in Bone
CANALIS, E., & DELANY, A. M. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04204.x · Cited by 406
Research works printed but not linked: 1
- Shaker JL, Lukert BP. Osteoporosis associated with excess glucocorticoids. Endocrinol Metab Clin North Am 2005, 34: 341–56. · DOI
Cited by
Valassi, E., Santos, A., Yaneva, M., Tóth, M., Strasburger, C. J., Chanson, P., Wass, J. A. H., Chabre, O., Pfeifer, M., Feelders, R. A., et al. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0272 · Cited by 402
Sarcopenic obesity in older adults: a clinical overview
Prado, C. M., Batsis, J. A., Donini, L. M., Gonzalez, M. C., & Siervo, M. (2024) · Nature Reviews Endocrinology · doi:10.1038/s41574-023-00943-z · Cited by 355
“Furthermore, cortisol can negatively affect bone health 73 and exacerbate age-related bone density decline, possibly contributing to the development of osteosarcopenic obesity 74 .”
Chiodini, I., Morelli, V., Masserini, B., Salcuni, A. S., Eller-Vainicher, C., Viti, R., Coletti, F., Guglielmi, G., Battista, C., Carnevale, V., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0468 · Cited by 168
Self-citationResmini, E., Minuto, F., Colao, A., & Ferone, D. (2009) · Acta Diabetologica · doi:10.1007/s00592-009-0112-9 · Cited by 147
“corticoid excess leads to a recovery of bone mass which is, however, often incomplete and delayed, although it reduces the risk of osteoporotic fractures [32].”
BackgroundEller-Vainicher, C., Morelli, V., Ulivieri, F. M., Palmieri, S., Zhukouskaya, V. V., Cairoli, E., Pino, R., Naccarato, A., Scillitani, A., Beck-Peccoz, P., et al. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1648 · Cited by 143
Self-citationMorelli, V., Eller-Vainicher, C., Salcuni, A. S., Coletti, F., Iorio, L., Muscogiuri, G., Della Casa, S., Arosio, M., Ambrosi, B., Beck-Peccoz, P., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.398 · Cited by 135
“In recent years, the majority((5-9,31)) but not all((10)) cross-sectional studies have suggested that SH is associated with an increased prevalence of osteoporosis.”
BackgroundResultInfluentialSelf-citationNunes, M.-L., Vattaut, S., Corcuff, J.-B., Rault, A., Loiseau, H., Gatta, B., Valli, N., Letenneur, L., & Tabarin, A. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1542 · Cited by 129
Biver, E., Chopin, F., Coiffier, G., Funck‐Brentano, T., Bouvard, B., Garnero, P., & Cortet, B. (2011) · Joint Bone Spine · doi:10.1016/j.jbspin.2011.05.003 · Cited by 114
Advances in the epidemiology, pathogenesis, and management of Cushing’s syndrome complications
Arnaldi, G., Mancini, T., Tirabassi, G., Trementino, L., & Boscaro, M. (2012) · Journal of Endocrinological Investigation · doi:10.1007/bf03345431 · Cited by 94
“GC also enhance the expression of colony-stimulating factor, which in the presence of RANK-L induces osteoclastogenesis (123).”
Trementino, L., Appolloni, G., Ceccoli, L., Marcelli, G., Concettoni, C., Boscaro, M., & Arnaldi, G. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2520-5 · Cited by 89
“As previously reported, bone loss seems to be related to the unbalanced ratio between bone apposition (reduced) and bone resorption (normal/increased) caused by GC excess and reflected by the decreased serum levels of osteocalcin and alkaline phosphatase found in CS patients [3,4,6].”
BackgroundResultInfluentialThe clinical significance of adrenal incidentalomas
Androulakis, I. I., Kaltsas, G., Piaditis, G., & Grossman, A. B. (2011) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2010.02436.x · Cited by 61
Salcuni, A. S., Morelli, V., Eller Vainicher, C., Palmieri, S., Cairoli, E., Spada, A., Scillitani, A., & Chiodini, I. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-0977 · Cited by 72
Self-citationChiodini, I., Viti, R., Coletti, F., Guglielmi, G., Battista, C., Ermetici, F., Morelli, V., Salcuni, A., Carnevale, V., Urbano, F., et al. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03310.x · Cited by 72
Self-citationMechanisms in endocrinology: endogenous subclinical hypercortisolism and bone: a clinical review
Chiodini, I., Vainicher, C. E., Morelli, V, Palmieri, S., Cairoli, E., Salcuni, A. S., Copetti, M., & Scillitani, A. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0289 · Cited by 73
Self-citationBarahona, M.-J., Sucunza, N., Resmini, E., Fernández-Real, J.-M., Ricart, W., Moreno-Navarrete, J.-M., Puig, T., Wägner, A. M., Rodriguez-Espinosa, J., Farrerons, J., et al. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090505 · Cited by 61
Skeletal Diseases in Cushing’s Syndrome: Osteoporosis versus Arthropathy
Kaltsas, G., & Makras, P. (2010) · Neuroendocrinology · doi:10.1159/000314298 · Cited by 71
DIAGNOSIS OF ENDOCRINE DISEASE: Evaluation of bone fragility in endocrine disorders
Eller-Vainicher, C., Falchetti, A., Gennari, L., Cairoli, E., Bertoldo, F., Vescini, F., Scillitani, A., & Chiodini, I. (2019) · European Journal of Endocrinology · doi:10.1530/eje-18-0991 · Cited by 69
Self-citationIacopo, C., Falchetti, A., Merlotti, D., Cristina, E.-V., & Gennari, L. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1772051 · Cited by 64
“mone deficiency may contribute to bone loss, even though in both CS and SH patients fractures often occur regardless of eugonadal status [42,57].”
BackgroundTreatment of skeletal impairment in patients with endogenous hypercortisolism: when and how?
On behalf of ABC Group, Scillitani, A., Mazziotti, G., Di Somma, C., Moretti, S., Stigliano, A., Pivonello, R., Giustina, A., & Colao, A. (2014) · Osteoporosis International · doi:10.1007/s00198-013-2588-y · Cited by 62
Self-citationAppelman‐Dijkstra, N. M., Claessen, K. M. J. A., Hamdy, N. A. T., Pereira, A. M., & Biermasz, N. R. (2014) · Clinical Endocrinology · doi:10.1111/cen.12493 · Cited by 45
“We have previously shown that 2 years of physiological dose of rhGH in GHD adults increased bone turnover in favor of bone formation, as reflected by a significant increase in BMD (23) that sustained after 7 years of treatment (24).”
BackgroundDirect Surface Enhanced Raman Spectroscopic Detection of Cortisol at Physiological Concentrations
Moore, T. J., & Sharma, B. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.9b04532 · Cited by 52
Bedford, J. L., Prior, J. C., & Barr, S. I. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2497 · Cited by 51
Leptin-Mediated Neuroendocrine Alterations in Anorexia Nervosa: Somatic and Behavioral Implications
Müller, T. D., Föcker, M., Holtkamp, K., Herpertz‐Dahlmann, B., & Hebebrand, J. (2008) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2008.07.002 · Cited by 51
Treatment options for glucocorticoid-induced osteoporosis
Chiodini, I., Merlotti, D., Falchetti, A., & Gennari, L. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1721467 · Cited by 48
“In fact, they can induce hypogonadism, which may negatively impact on bone turnover [41].”
BackgroundSelf-citationMusculoskeletal complications of Cushing syndrome
Leszczyńska, D., Szatko, A., Papierska, L., Zgliczyński, W., & Glinicki, P. (2023) · Reumatologia/Rheumatology · doi:10.5114/reum/169889 · Cited by 47
“The severity of GIO is less pronounced in patients treated with high dose 6-methylprednisolone intravenous pulse therapy than daily oral GC therapy [54].”
BackgroundInfluentialBone turnover in patients with endogenous Cushing’s syndrome before and after successful treatment
Szappanos, Á., Tõke, J., Lippai, D., Patócs, A., Igaz, P., Szücs, N., Fütő, L., Gláz, E., Rácz, K., & Tóth, M. (2009) · Osteoporosis International · doi:10.1007/s00198-009-0978-y · Cited by 43
“[15].”
Understanding and managing secondary osteoporosis
Colangelo, L., Biamonte, F., Pepe, J., Cipriani, C., & Minisola, S. (2019) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2019.1575727 · Cited by 39
“Adrenal gland-induced osteoporosis is caused by Cushing syndrome [24] and less frequently by hyperaldosteronism [25].”
BackgroundPrediction of Vertebral Fractures in Patients With Monolateral Adrenal Incidentalomas
Morelli, V., Eller-Vainicher, C., Palmieri, S., Cairoli, E., Salcuni, A. S., Scillitani, A., Carnevale, V., Corbetta, S., Arosio, M., Della Casa, S., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1423 · Cited by 33
Self-citationKim, B., Kwak, M. K., Ahn, S. H., Kim, J. S., Lee, S. H., & Koh, J. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4608-4 · Cited by 30
The Relationship Between 24-h Urinary Cortisol and Bone in Healthy Young Women
Bedford, J. L., & Barr, S. I. (2009) · International Journal of Behavioral Medicine · doi:10.1007/s12529-009-9064-2 · Cited by 27
“Subclinical hypercortisolism, as found with adrenal adenoma, shows similar patterns [2].”
InfluentialEndogenous Glucocorticoid Metabolism in Bone: Friend or Foe
Martin, C., Cooper, M. S., & Hardy, R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.733611 · Cited by 26
Chronic arsenic intoxication diagnostic score (CAsIDS)
Dani, S. U., & Walter, G. F. (2017) · Journal of Applied Toxicology · doi:10.1002/jat.3512 · Cited by 26
Assessment of non-traumatic vertebral fractures in Cushing’s syndrome patients
Apaydın, T., & Yavuz, D. G. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01496-y · Cited by 25
Corticosteroid-Induced Osteoporosis: An Update for Dermatologists
Clarke, B. L. (2012) · American Journal of Clinical Dermatology · doi:10.2165/11594250-000000000-00000 · Cited by 20
“Patients with endogenous hypercortisolemia due to subclinical or overt Cushing syndrome also lose BMD and have increased vertebral and nonvertebral fractures.([111-115]) Bone loss may be more severe in adrenal- than pituitary-dependent Cushing syndrome.”
BackgroundTen tips on how to assess bone health in patients with chronic kidney disease
Jørgensen, H. S., Lloret, M. J., Lalayiannis, A. D., Shroff, R. C., Evenepoel, P., Bacchetta, J., Bravenboer, N., Ferreira, A., Fusaro, M., Haarhaus, M. L., et al. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae093 · Cited by 19
Peng, W., Li, Z., Guan, Y., Wang, D., & Huang, S. (2015) · Aging & Mental Health · doi:10.1080/13607863.2015.1033680 · Cited by 19
Physiology and Pathophysiology of the HPA Axis
de Castro, M., Elias, L. L. K., Elias, P. C. L., & Moreira, A. C. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-449-4_1 · Cited by 19
Zimmer, K. E., Kraugerud, M., Aleksandersen, M., Gutleb, A. C., Østby, G. C., Dahl, E., Berg, V., Skaare, J. U., Olsaker, I., & Ropstad, E. (2011) · Environmental Toxicology · doi:10.1002/tox.20703 · Cited by 17
“The hor- mone also interferes with immune reactions and bone mineral density and processes in the central nervous system (O’Connor et al., 2000; Chiodini et al., 2008).”
BackgroundStachowska, B., Kuliczkowska-Płaksej, J., Kałużny, M., Grzegrzółka, J., Jończyk, M., & Bolanowski, M. (2020) · Endocrine · doi:10.1007/s12020-020-02468-1 · Cited by 15
Drug-Induced Osteoporosis in the Older Adult
O’Connell, M. B., Borgelt, L. M., Bowles, S. K., & Vondracek, S. F. (2010) · Aging Health · doi:10.2217/ahe.10.42 · Cited by 15
Hypercortisolism as a Potential Concern for Submariners
Reini, S. A. (2010) · Aviation Space and Environmental Medicine · doi:10.3357/asem.2875.2010 · Cited by 13
Cushing’s syndrome in pregnancy
Holgado-Galicia, M. V., Magno, J. D., Valdenor, C., Isip-Tan, I. T., & Lim-Abrahan, M. A. (2011) · BMJ Case Reports · doi:10.1136/bcr.01.2011.3720 · Cited by 12
“23 This would explain the fi nding of pathologic fracture in our second case.”
Trementino, L., Ceccoli, L., Concettoni, C., Marcelli, G., Michetti, G., Boscaro, M., & Arnaldi, G. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0126-1 · Cited by 11
Corrêa, M. G., Campos, M. L. G., Marques, M. R., Ambrosano, G. M. B., Casati, M. Z., Nociti, F. H., & Sallum, E. A. (2013) · Journal of Periodontology · doi:10.1902/jop.2013.130383 · Cited by 11
Giordano, R., Parasiliti‐Caprino, M., Loli, P., & Giustina, A. (2024) · Journal of Endocrinological Investigation · doi:10.1007/s40618-024-02450-y · Cited by 9
“Correctly defined screening thus applies to truly asymp - tomatic mild hypercortisolism [45].”
Persistent Comorbidities in Cushing’s Syndrome after Endocrine Cure
Resmini, E. (2014) · Advances in Endocrinology · doi:10.1155/2014/231432 · Cited by 9
“It is known that any chronic GC excess reduces bone mass [76–79].”
BackgroundPoonuru, S., Findling, J. W., & Shaker, J. L. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3712-6 · Cited by 9
“Sustained and prolonged hypercortisolism effects include bone architecture, geometry, and bone remodeling with initial increased bone resorption and subsequent decreased bone formation [15].”
BackgroundMooney, C. T., Shiel, R. E., Sekiya, M., Dunning, M., & Gunn, E. (2020) · Frontiers in Veterinary Science · doi:10.3389/fvets.2020.00311 · Cited by 8
“However, HAC in humans differs from that in dogs with respect to a high incidence of clinically significant osteoporosis (2, 3).”
BackgroundGianotti, L., Tassone, F., Pia, A. R., Bovio, S., Reimondo, G., Visconti, G., Terzolo, M., & Borretta, G. (2009) · Calcified Tissue International · doi:10.1007/s00223-009-9245-7 · Cited by 6
Hormonell bedingte Schenkelhalsspontanfraktur bei einer 28-jährigen Patientin
Bala, M., Bollheimer, C., Schölmerich, J., & Schäffler, A. (2009) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-009-1038-2 · Cited by 6
A Rare Presentation of Subclinical Cushing's Syndrome as a Pubic Fracture
Arduç, A., Dogan, B. A., Akbaba, G., Duran, İ. D., Küçükler, K., Işık, S., Özuğuz, U., Berker, D. S., & Güler, S. (2014) · Internal Medicine · doi:10.2169/internalmedicine.53.1489 · Cited by 6
“A bone mineral density (BMD) analysis revealed osteoporosis (lumbar total T score: -4.2, total femoral T score: -3.5, femoral neck T score: -3.4).”
BackgroundInfluentialZhang, J., Zeng, H., Fu, S., Shi, P., Wang, M., & Guo, L. (2016) · Biomedical Reports · doi:10.3892/br.2016.631 · Cited by 6
“However, the long-term administration of large quantities of glucocorticoids may result in glucocorticoid-induced osteoporosis by inhibiting the formation of osteoblasts, stimulating bone resorption and contributing to a negative calcium balance (2-4).”
Clinical Practice Patterns in Bone Health Assessment and Management in Endogenous Cushing's Syndrome
Behary, P., Raveendran, D., Nair, R., Marco, A. N. D., Papadopoulou, D., Wernig, F., Abbara, A., Meeran, K. M., Martin, N. M., Cox, J., et al. (2025) · Clinical Endocrinology · doi:10.1111/cen.70085 · Cited by 5
“Moreover, fragility fractures can be the presenting feature of otherwise silent CS [6], with a threefold increased fracture risk 2−3 years preceding CS diagnosis [12, 13].”
Osteoporosis in pituitary diseases: lessons for the clinic
Bolanowski, M., Jawiarczyk-Przybyłowska, A., & Halupczok-Żyła, J. (2014) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2015.983473 · Cited by 5
“It leads to inhibition of bone formation and decreases the amount of bone replaced in each remodeling cycle [42].”
BackgroundA General Mechano-Pharmaco-Biological Model for Bone Remodeling Including Cortisol Variation
Kahla, R. B., Barkaoui, A., Chafra, M., & Tavares, J. M. R. S. (2021) · Mathematics · doi:10.3390/math9121401 · Cited by 5
“Specifically, it exerts direct negative effects on bone mineral den ty (BMD) by affecting bone ell growth, disrupting the bone remodeling process, impairing calcium intestinal absorption and renal reabsorption, as well as by inhibiting activity of sex steroids [55].”
BackgroundBuccato, D. G., Ullah, H., Lellis, L. F. D., Piccinocchi, R., Baldi, A., Xiao, X., Arciola, C. R., Minno, A. D., & Daglia, M. (2024) · Molecules · doi:10.3390/molecules29030586 · Cited by 5
“It alters bone turnover, impairs intestinal absorption and renal reabsorption of calcium, and inhibits reproductive hormones in postmenopausal women [16].”
BackgroundMultiple Endocrine Neoplasia Syndromes
Newey, P. J., & Thakker, R. V. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804182-6.00038-1 · Cited by 5
Common ground: The overlap between Endocrinology and Rheumatology
Bracewell, C., Vila, J., Narayanan, K., & Kelly, C. A. (2009) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2009.04.004 · Cited by 3
“8% prevalence in one series [21]) and can precede the diagnosis by up to 2 years with up to 70% of patients sustaining at least one fracture overall [22].”
BackgroundOstéoarthropathies d'origine endocrinienne
Lambert, A.-S., Loffroy, R., Feydy, A., Thévenin, F., Merzoug, V., Méjean, N., Couaillier, J. F., Barral, F.-G., Chevrot, A., Drapé, J., et al. (2011) · EMC - Radiologie et imagerie médicale - Musculosquelettique - Neurologique - Maxillofaciale · doi:10.1016/s1879-8551(11)70851-x · Cited by 3
Osteoporosis and Somatization of Anxiety
Papanikou, M. (2013) · The European Journal of Counselling Psychology · doi:10.5964/ejcop.v2i2.32 · Cited by 2
“…axis homeostasis without the classical signs and symptoms of glucocorticoid excess, is a recently defined entity, which has been shown to be associated to increased bone resorption, bone loss, and high prevalence of vertebral fractures regardless of gonadal status (Chiodini et al., 2008).”
BackgroundBone metabolism disorders in endogenous Cushing syndrome
Cylke-Falkowska, K., & Stelmachowska‐Banaś, M. (2023) · Wiedza Medyczna · doi:10.36553/wm.155 · Cited by 1
“Fractures due to hypercortisolemia are noted in the first few years of diseasewhile densitometric improvement is observed within 2 years of recovery (30, 34, 35).”
BackgroundPansini, V., Herbinet, P., Cortet, B., Lefebvre, G., & Cotten, A. (2013) · Elsevier eBooks · doi:10.1016/b978-2-294-71924-0.00010-3 · Cited by 1
Timón, R., Olcina, G. J., Tomás-Carús, P., Raimundo, A. M. D. M., Maynar, J. I., & Maynar-Mariño, M. (2012) · Endocrine · doi:10.1007/s12020-012-9604-4 · Cited by 1
Posttreatment Management of Cushing’s Disease
Prete, A., & Salvatori, R. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804340-0.00009-7 · Cited by 1
WITHDRAWN: Osteoporosis and Somatization of Anxiety
Papanikou, M., & Kotsopoulou, A. (2014) · Procedia - Social and Behavioral Sciences · doi:10.1016/j.sbspro.2014.01.010 · Cited by 1
RetractedZgheib, S. (2014) · theses.fr (ABES) · doi:10.70675/8313b145z3285z42e3za311zfed97c606f34 · Cited by 1
Lauterbach, S., & Kohlmann, T. (2011) · Primary Health Care Open Access · doi:10.4172/2167-1079.1000103
Physical Exercise for Secondary Osteoporosis
Mina, D. S. (2012) · The Open Bone Journal · doi:10.2174/1876525401204010001
“Many disorders and treatments well-known to cause secondary osteoporosis, including: hypogonadism (idiopathic or induced chemically or surgically for cancer treatment) [2126], glucocorticoid use [27-29], hyperthyroidism [30-32], Cushing’s disease [33, 34], and diabetes mellitus [35, 36] (See Table 1 for a summary of m…”
BackgroundHiperplasia adrenal macronodular bilateral ACTH independiente y síndrome de Cushing subclínico
Berdonces, M. C., Avilés-Pérez, M. D., García‐Martin, A., & Muñoz‐Torres, M. (2011) · Medicina Clínica · doi:10.1016/j.medcli.2011.05.003
Auszug der Leitlinieninhalte 2014 bezüglich einer Glukokortikoidtherapie: DVO-Leitlinie Osteoporose
Siggelkow, H. (2016) · Osteologie/Osteology · doi:10.1055/s-0037-1619031
Adrenal Cushing’s Syndrome: Updates on Overt and Mild Hypercortisolism
Escobar, J. S., Ravikumar, A., & Levine, A. C. (2017) · Contemporary Endocrinology · doi:10.1007/978-3-319-62470-9_10
Adrenal Function and Skeletal Regulation
Chiodini, I., Battista, C., Cairoli, E., Eller-Vainicher, C., Morelli, V., Palmieri, S., Salcuni, A. S., & Scillitani, A. (2018) · Springer eBooks · doi:10.1007/978-3-319-75110-8_7
Self-citation(2009) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e32832f731f
From Minor Domestic Accident to Adrenal Tumours Related Osteoporosis
Carsote, A. V. M. (2015) · Primary Health Care Open Access · doi:10.4172/2167-1079.1000i103
Schneider, A. (2023) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-9705
Erdemir, U., Kayalıdere, E. E., Alshawi, A., Özünal, Z. G., Yıldız, S. Ö., & Yıldız, E. (2024) · Malaysian Dental Journal · doi:10.4103/mdj.mdj_7_24
Impacto de un programa educativo para el paciente con síndrome de Cushing: Estudio Multicéntrico
Momblán, M., & Martínez-Momblán, M.-A. (2013) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
Bone Morphogenetic Protein Signalling in Adult Lung Epithelial Cells
Molloy, E. L. (2008) · Maynooth University ePrints and eTheses Archive (Maynooth University)
Barahona, M. J., & de Medicina, U. A. D. B. D. (2010) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya)
Multiple endocrine neoplasia syndromes
Newey, P. J., & Thakker, R. V. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13683-2.00033-5
Frigerio, F., & Donini, L. M. (2026) · Endocrinology · doi:10.1007/978-3-030-71067-5_23-1
Osteoporosi nelle malattie endocrine
Cianferotti, L., & Marcocci, C. (2009) · Springer eBooks · doi:10.1007/978-88-470-1357-5_13
Metadata
- Authors
- Chiodini, I., Torlontano, M., Carnevale, V., Trischitta, V., & Scillitani, A.
- Affiliations
- University of Milan (IT)
- Casa Sollievo della Sofferenza (IT)
- Corresponding author
- Scillitani, A.
- Venue
- Journal of Endocrinological Investigation
- Published
- 2008-03
- Volume
- 31
- Issue
- 3
- Pages
- 267-276
- ISSN
- 0391-4097 (ISSN-L)
- 1720-8386
- OpenAlex
- W2152174465
- Cited by
- 78
- References
- 69
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 5 · 2023: 2 · 2021: 3 · 2020: 4 · 2019: 3 · 2018: 2 · 2017: 4 · 2016: 5 · 2015: 3 · 2014: 6 · 2013: 6 · 2012: 5
- FWCI
- 1.45
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Journal of Endocrinological Investigation (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal Regulation and Hypertension
- Keywords
- endogenous hypercortisolism, Cushing's syndrome, subclinical hypercortisolism, osteoporosis, osteoporotic fractures, bone loss, bone resorption, trabecular bone, vertebral fractures, bone metabolism, hypothalamic-pituitary-adrenal axis, bisphosphonates, fracture screening
- MeSH terms
- Adult, Bone Diseases, Bone Resorption, Calcium, Cushing Syndrome, Female, Gonadotropins, Humans, Intestinal Absorption, Male, Osteoporosis, Risk Factors, Biomarkers, Bone Density, Spinal Fractures, Bone Remodeling, Human Growth Hormone, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.